ProMIS Neurosciences Secures $12 Million in Private Placement Financing to Advance Alzheimer's Therapeutic Development

Reuters
28 Jul
ProMIS Neurosciences Secures $12 Million in Private Placement Financing to Advance Alzheimer's Therapeutic Development

ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a private placement financing. The company has entered into a purchase agreement with existing institutional and accredited investors to issue and sell approximately $3.0 million of warrants through a private investment in public equity $(PIPE)$ financing. The Warrants, sold at $0.1875 per share, have an exercise price of $1.25 per share, are immediately exercisable, and will expire five years from issuance. ProMIS anticipates gross proceeds from the PIPE financing, combined with proceeds from the exercise of existing warrants, to total approximately $12.0 million. The funds will be utilized to advance the clinical development of PMN310, the company's lead therapeutic candidate, and for working capital and general corporate expenses. The financing is expected to close soon, pending customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9501161-en) on July 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10